Pfizer's Centers for Therapeutic Innovation Program (CTI) has announced its second call for proposals. A Pfizer representative will facilitate this on-site workshop, present more about the program, and discuss how Einstein researchers can participate. A previous Einstein awardee (Dr. Bettina Fries) will also be available to provide tips on applying and give in sights into the program.
CTI is an innovative collaboration model, supported by Pfizer, that allows investigators to advance research projects from the lab into the clinic. CTI projects are supported by significant resources from Pfizer – from technologies, antibody/peptide libraries, post-doc support, among other resources. The collaboration is designed to jointly engage in Research Programs that identify protein biologic therapeutic candidates directed at targets/pathways that culminate in Phase I clinical trials that demonst rate Proof-of-Mechanism.
Pfizer-CTI is looking to fund projects that involve (a) biologic candidates (monoclonal antibodies, peptides, proteins), (b) novel mechanisms addressing areas of unmet medical need and (c) strong link of pathway to disease. This time around Pfizer-CTI has well defined focus areas. Their focus areas are (1) Autoimmunity with a specific focus on Systemic Lupus Erythematosus/Lupus Nephritis), (2) Renal Disease (Kidney Injury/Lupus Glomerulonephritis, IgA Nephropathy), (3) Cardiovascular (Congestive Heart Failure, Post-Myocardial Infarction and Acute Coronary Syndrome), and (4) Rare Diseases.
If you are interested in applying for the program and have questions, please contact Ece Auffarth, Ph.D. email@example.com